Your browser doesn't support javascript.
loading
Profiles of Kelch mutations in Plasmodium falciparum across South Asia and their implications for tracking drug resistance.
Chhibber-Goel, Jyoti; Sharma, Amit.
Afiliação
  • Chhibber-Goel J; Molecular Medicine Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, 110067, India. Electronic address: jyoti.chhibber@gmail.com.
  • Sharma A; Molecular Medicine Group, International Centre for Genetic Engineering and Biotechnology, New Delhi, 110067, India. Electronic address: amitpsharma68@gmail.com.
Article em En | MEDLINE | ID: mdl-31606696
ABSTRACT
Artemisinin-based combination therapy (ACT) offers highly successful treatment of malaria. Emergence and spread of Plasmodium falciparum (Pf) parasites with decreased susceptibility to ACT in South-East Asia has caused concern worldwide. The current accepted criteria to assess artemisinin (ART) resistance relies upon data on treatment failure, delayed parasite clearance at day 3 (DPC3), parasite clearance half-life (PCHL) and in-vitro/ex-vivo ring stage survival assays (RSAs). Interestingly, some studies suggest that DPC3 does not provide a distinct separation between ART sensitive/resistant strains, and RSA differences may also be inconclusive. More recently, recrudescence of ART treated Pf, independent of the presence of Kelch 13 (K13) mutation (C580Y), has been reported in the monkey malaria model suggesting that genes other than K13 like coronin, dhps, dhfr, crt, mdr1 and plasmepsin1 may contribute towards ACT failure. Here we have collated the distribution of K13 mutants from Pf strains in South Asia. A total of fifty Pf-K13 mutations have been studied for ART resistance in South Asia of which nine have been validated while eleven are potentials for ART resistance. The remaining thirty K13 mutations have been reported from various locations in South Asia but lack corroborative clinical data on ART resistance/ACT failure. Of the fifty, fourteen K13 mutations have been identified in India including four novel mutations (S549Y, G625R, N657H, D702N). Structural mapping of these K13 mutations does not offer any coherent explanation for their contribution towards ART resistance as they are scattered in the K13 structure. Thus, K13 mutations likely provide only a partial synopsis, and we propose that all suspect cases of ACT failure be assessed by 1) DPC3, 2) PCHL, 3) in-vitro/ex-vivo RSAs and 4) GWAS data in an effort to annotate the resistance status of the parasites. These efforts may help in surveillance and containment of ART resistance/ACT failure in South Asia.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Plasmodium falciparum / Resistência a Medicamentos / Artemisininas / Repetição Kelch / Mutação / Antimaláricos Tipo de estudo: Prognostic_studies País/Região como assunto: Asia Idioma: En Revista: Int J Parasitol Drugs Drug Resist Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Plasmodium falciparum / Resistência a Medicamentos / Artemisininas / Repetição Kelch / Mutação / Antimaláricos Tipo de estudo: Prognostic_studies País/Região como assunto: Asia Idioma: En Revista: Int J Parasitol Drugs Drug Resist Ano de publicação: 2019 Tipo de documento: Article